Xcout Intel
Arch Biopartners Inc.
Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Subscribe to see Arch Biopartners Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Arch Biopartners Inc. at a glance
Arch Biopartners Inc. is a biotech company headquartered in Saint Louis, Canada. It is publicly listed (ARCH) with a market capitalisation of $41.1M. Xcout tracks 25 named people at Arch Biopartners Inc., including Paul A Lang (Chief Executive Officer & Director).
Arch Biopartners Inc. leadership
- Paul A LangChief Executive Officer & Director
- John T. DrexlerPresident, Chief Operating Officer & Director
- Keith WilliamsGroup President of Western Operations & President of Thunder Basin Coal Company
- George J. Schuller Jr.Senior Vice President & Chief Operating Officer
- Matthew C. GiljumSenior Vice President & Chief Financial Officer
- Andrew BishopChief Financial Officer, Director
19 more named people on record for Arch Biopartners Inc., with roles, board committees and tenure — see the full roster →
Arch Biopartners Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Arch Biopartners Inc. competitors
A few of Arch Biopartners Inc.'s closest competitors — see the full list of competitors and alternatives →
Asep Medical Holdings Inc., operating primarily through its subsidiary ASEP Medical Inc., is dedicated to advancing both a rapid diagnostic system for Sepsis and a range of peptide-based therapeutic treatments applicable across various medical conditions. The company, initially incorporated in 2020 under the name Trenchant Life Sciences Investment Corp., later rebranded to its present title, Asep Medical Holdings Inc. Its corporate base of operations is located in Vancouver, Canada.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Mesentech Inc. is an active for-profit biotechnology company focused on drug pipelines, therapeutic areas, and proprietary technology platforms. Headquartered in Vancouver, British Columbia, Canada, the company operates with a small team specializing in clinical research and development.
ArrePath is a biotechnology research company based in Princeton, New Jersey, focusing on AI-enabled oral small-molecule discovery. The company uses proprietary artificial intelligence and machine learning workflows proven in antibacterial discovery.
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Get Arch Biopartners Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Arch Biopartners Inc. in Xcout Intel
- 25 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access